{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:54:10Z","timestamp":1781758450376,"version":"3.54.5"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oncology clinical trials, regardless of success in meeting their primary endpoint, often suffer from spin\u2014the misrepresentation of research findings. Despite dramatic improvements in myeloma outcomes, numerous recent myeloma trials have failed to meet their primary endpoints while others have amplified marginally positive findings. A thorough evaluation of reporting practices and spin in myeloma randomized controlled trials (RCTs) is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We performed a cross-sectional analysis of myeloma RCTs that began enrollment in January 2015 or later, with final search conducted in March 2025. Reporting of prespecified primary endpoints and sample size calculations was abstracted. Two reviewers screened for the presence of spin, defined as at least one reporting practice that could mislead readers by emphasizing benefit or minimizing unfavorable findings. Multivariable logistic regression was used to determine factors associated with spin. The methods were registered on the Open Science Framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 82 screened studies, 71 RCTs were included. The prespecified primary endpoint was statistically significant in 46 trials (64.8%). Sample size calculations were reported in 51 trials (71.8%), and conclusions aligned with primary endpoint results in 63 trials (88.7%). Spin occurred in 25 trials (35.2%), most commonly through optimistic language and emphasis on secondary\/subgroup findings. In multivariable analysis, meeting the prespecified primary endpoint was associated with lower odds of spin (adjusted odds ratio [OR] = 0.15; 95% CI, 0.03-0.70; P\u2009=\u2009.016).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Spin affected one-third of contemporary myeloma RCTs and was strongly associated with nonsignificant primary endpoints, highlighting the need for primary endpoint-aligned interpretation and transparent sample size reporting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag221","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:22:09Z","timestamp":1780312929000},"source":"Crossref","is-referenced-by-count":0,"title":["Reporting of primary endpoint and associated spin in randomized myeloma trials"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-7831","authenticated-orcid":false,"given":"Mitch","family":"Singstock","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Utah , Salt Lake City, UT, 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5628-3829","authenticated-orcid":false,"given":"Abul Hasan Shadali","family":"Abdul Khader","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mercy Catholic Medical Center , PA, 19023,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8829-8179","authenticated-orcid":false,"given":"Cole","family":"Wayant","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Anschutz , Denver, CO, 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-8668","authenticated-orcid":false,"given":"Mackenzie","family":"Lemieux","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah , Salt Lake City, UT, 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-2241","authenticated-orcid":false,"given":"Maria","family":"Mainou","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence Based Medicine Unit, Aristotle University of Thessaloniki , Thessaloniki, 54124,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT, 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026061800213311100_oyag221-B1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"2026061800213311100_oyag221-B2","doi-asserted-by":"crossref","first-page":"104529","DOI":"10.1016\/j.critrevonc.2024.104529","article-title":"Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: a systematic review","volume":"204","author":"Mainou","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026061800213311100_oyag221-B3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ajh.26166","article-title":"Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review","volume":"96","author":"Mohyuddin","year":"2021","journal-title":"Am J Hematol"},{"key":"2026061800213311100_oyag221-B4","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.2010.651","article-title":"Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes","volume":"303","author":"Boutron","year":"2010","journal-title":"JAMA"},{"key":"2026061800213311100_oyag221-B5","doi-asserted-by":"crossref","first-page":"102821","DOI":"10.1016\/j.critrevonc.2019.102821","article-title":"Evaluation of spin in oncology clinical trials","volume":"144","author":"Wayant","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026061800213311100_oyag221-B6","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mds636","article-title":"Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer","volume":"24","author":"Vera-Badillo","year":"2013","journal-title":"Ann Oncol"},{"key":"2026061800213311100_oyag221-B7","doi-asserted-by":"crossref","first-page":"e1001308","DOI":"10.1371\/journal.pmed.1001308","article-title":"Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study","volume":"9","author":"Yavchitz","year":"2012","journal-title":"PLoS Med"},{"key":"2026061800213311100_oyag221-B8","doi-asserted-by":"crossref","first-page":"100411","DOI":"10.1016\/j.jcpo.2023.100411","article-title":"Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology","volume":"36","author":"Sharma","year":"2023","journal-title":"J Cancer Policy"},{"key":"2026061800213311100_oyag221-B9","doi-asserted-by":"crossref","first-page":"e2002173","DOI":"10.1371\/journal.pbio.2002173","article-title":"\u201cSpin\u201d in published biomedical literature: a methodological systematic review","volume":"15","author":"Chiu","year":"2017","journal-title":"PLoS Biol"},{"key":"2026061800213311100_oyag221-B10","doi-asserted-by":"crossref","first-page":"e2135765","DOI":"10.1001\/jamanetworkopen.2021.35765","article-title":"Misleading reporting (spin) in noninferiority randomized clinical trials in oncology with statistically not significant results: a systematic review","volume":"4","author":"Ito","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026061800213311100_oyag221-B11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von Elm","year":"2007","journal-title":"Lancet"},{"key":"2026061800213311100_oyag221-B12","first-page":"1776","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"31","author":"Hopewell","year":"2025","journal-title":"Lancet"},{"key":"2026061800213311100_oyag221-B13","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ajh.26361","article-title":"A phase I\/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (alliance A061202)","volume":"96","author":"Voorhees","year":"2021","journal-title":"Am J Hematol"},{"key":"2026061800213311100_oyag221-B14","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood-2019-131223","article-title":"Phase II trial of ixazomib and dexamethasone versus ixazomib, dexamethasone and lenalidomide, randomized with NFKB2 rearrangement. (proteasome inhibitor NFKB2 rearrangement driven trial, PINR)","volume":"134","author":"Bernal-Mizrachi","year":"2019","journal-title":"Blood"},{"key":"2026061800213311100_oyag221-B15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s44313-024-00025-7","article-title":"Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant-ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM-2002 study","volume":"59","author":"Huh","year":"2024","journal-title":"Blood Res"},{"key":"2026061800213311100_oyag221-B16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-021-00593-2","article-title":"Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized phase 2 trial","volume":"12","author":"Dimopoulos","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026061800213311100_oyag221-B17","doi-asserted-by":"crossref","first-page":"358.e1\u2013358","DOI":"10.1016\/j.jtct.2022.07.007","article-title":"A multicenter phase II, double-blind, placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for High-Risk multiple myeloma: results of the blood and marrow transplant clinical trials network 1302 trial","volume":"29","author":"Bashir","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026061800213311100_oyag221-B18","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"2026061800213311100_oyag221-B19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/01.coc.0000436085.23342.2d","article-title":"Sample size calculation in oncology trials: quality of reporting and implications for clinical cancer research","volume":"38","author":"Bariani","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"2026061800213311100_oyag221-B20","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2014.56.7503","article-title":"Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial","volume":"32","author":"Boutron","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026061800213311100_oyag221-B21","doi-asserted-by":"crossref","first-page":"c117","DOI":"10.1136\/bmj.c117","article-title":"Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses","volume":"340","author":"Sun","year":"2010","journal-title":"BMJ"},{"key":"2026061800213311100_oyag221-B22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2026061800213311100_oyag221-B23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026061800213311100_oyag221-B24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"2026061800213311100_oyag221-B25","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026061800213311100_oyag221-B26","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"2026061800213311100_oyag221-B27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"key":"2026061800213311100_oyag221-B28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026061800213311100_oyag221-B29","doi-asserted-by":"crossref","first-page":"e1553","DOI":"10.1136\/bmj.e1553","article-title":"Credibility of claims of subgroup effects in randomised controlled trials: systematic review","volume":"344","author":"Sun","year":"2012","journal-title":"BMJ"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag221\/68457142\/oyag221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag221\/68457142\/oyag221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag221\/68457142\/oyag221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:21:43Z","timestamp":1781756503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag221\/8700289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag221","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,2]]},"article-number":"oyag221"}}